Oppenheimer & Co. Inc. Acquires Shares of 11,875 UroGen Pharma Ltd. (NASDAQ:URGN)

Oppenheimer & Co. Inc. acquired a new stake in UroGen Pharma Ltd. (NASDAQ:URGN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,875 shares of the company’s stock, valued at approximately $126,000. Oppenheimer & Co. Inc. owned 0.05% of UroGen Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of URGN. BNP Paribas Financial Markets increased its stake in UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after purchasing an additional 5,890 shares during the period. Intech Investment Management LLC acquired a new position in UroGen Pharma in the third quarter valued at $155,000. Verition Fund Management LLC acquired a new position in UroGen Pharma in the third quarter valued at $168,000. SG Americas Securities LLC increased its stake in UroGen Pharma by 44.1% in the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock valued at $216,000 after purchasing an additional 6,207 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in UroGen Pharma in the third quarter valued at $249,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the sale, the insider now owns 145,666 shares of the company’s stock, valued at $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on URGN shares. D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a research note on Tuesday, February 18th. HC Wainwright reiterated a “buy” rating and set a $64.00 price target on shares of UroGen Pharma in a research note on Tuesday, February 25th. Finally, LADENBURG THALM/SH SH started coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $40.00.

UroGen Pharma Stock Down 3.6 %

URGN stock opened at $9.82 on Monday. The company has a market cap of $230.32 million, a P/E ratio of -3.12 and a beta of 1.12. UroGen Pharma Ltd. has a 52 week low of $9.03 and a 52 week high of $20.70. The company’s 50-day moving average price is $10.45 and its 200 day moving average price is $11.76. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.